- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02058810
Nasal High Flow at Acute Hart Failure
Does the Use of Optiflow High Flow Oxygen on Patients With Acute Cardial Decompensation (NYHA Classification Stage III-IV) Allow for Quicker Improvement of the Organ Dysfunction Than Conventional Standard-Oxygen-Insufflation-Therapy?
The pilot study aims to compare the results of using a new respirator (OPTIFLOW TM-High-Flow-Machine) with those from Standard-Oxygen-Therapy during the stabilization of patients who have been hospitalized due to acute heart failure. We expect a faster and more effective stabilization after acute cardial decompensation among the patients with the High-Flow-machine.
The study should show whether the use of High-Flow-Therapy leads to a relevant improvement in terms of objective clinical parameters of heart failure like those for cardial-renal syndrome, changes in the nt-pro-BNP, weight loss, changes in the diameter of the inferior vena cava, in terms of the degree of shortness of breath and decompensation, and whether subjective clinical symptoms like dyspnea and quality of life differ between the two groups of patients.
The investigators see the primary outcome of the study as the improvement of the cardial-renal syndrome as a sign of the more effective stabilisation compared to the standard therapy. Furthermore, the investigators expect a quicker decrease in serum creatinine and an improvement in the creatinine clearance through therapy with the High-Flow-Machine. In terms of secondary outcomes of the study, the investigators are interested in also comparing e.g., the duration of hospital stays, 90-day mortality, and rehospitalisation within three months. Here, the investigators expect a quicker improvement in the subjective shortness of breath of the patients who are treated using the Hifh-Flow-Machine. Moreover, we believe that along with the individual subjective improvements (quality of life survey), the patients will experience a quicker release from the hospital and in this way, lead to a healthcare economic improvement among patients with repeated hospitalizations who usually have chronic problems.
It is also of great interest to us, whether the biomarker BNP is an appropriate parameter for determining the faster stabilization of the patient and whether the degree of improvement of subjective dyspnea is correlated with the time needed until the patient has been stabilised.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Primary endpoint:
Improvement of the cardiorenal syndrome type1 measured by the improvement of creatine clearance and the Serum-Creatinin of patients undergoing High-Flow treatment.
Secondary endpoints:
Worsening of cardiac insufficiency (application of catecholamines, need of NIV, intubation, death) Duration of hospital stay (in days) 90-day mortality Readmittance to hospital within 3 months Intrathoracic bloodvolume at hospital discharge Change of dyspnea at 3h, 6h, 24h > VAS-0-100 (visual analog scale) Change in the diameter of the IVC (inferior vena cava) as a non-invasive parameter for assessing the degree of decompensation Change in the BNP (hospital admission vs. discharge, after 3 months) Weight loss in hospital Amount of diuretics
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Sachsen Anhalt
-
Magdeburg, Sachsen Anhalt, Germany, 39120
- UHMagdeburg
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- patients with acute heartfailure NYHA III und IV
Exclusion Criteria:
- Patients wit respiratory insufficency and indication for mechanical ventilation
- Asthma bronchiale
- severe COPD
- cardiogenic shock (RR persisting< 90mmHg systolic or catecholamine application)
- renal dialysis
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Conventional nasal Oxygen
Conventional nasal Oxygen as needed
|
Other Names:
|
Other: Nasal high flow
Nasal high flow therapy with FiO2 40% and flow of 40l/min for at least 48h
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cardiorenal syndrome type 1
Time Frame: 3 Months
|
The acute deterioration of the cardial situation often leads to a consecutive deterioration of renal function.
The damage to renal function caused by acute cardial genesis is defined as cardiorenal syndrome type 1 [2].
In such cases, the venous congestion with heightened central venous pressure leads to disruption of renalfunction and possibly even to acute kidney failure [3, 4].
This is defined as cardiorenal syndrom with an increase in serumcreatine of >0,3 mg/dl and is associated with higher mortality and longer hospital stays [5].
|
3 Months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change of dyspnea
Time Frame: 3h, 6h, 24h
|
Change of dyspnea at 3h, 6h, 24h > VAS-0-100 (visual analog scale)
|
3h, 6h, 24h
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
90-day mortality
Time Frame: 90 days
|
Mortality after 90 days
|
90 days
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 300513
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Decompensated Heartfailure
-
Heartfelt TechnologiesRoyal Brompton & Harefield NHS Foundation TrustCompletedHeart Failure, Diastolic | Edema Brain | Decompensated HeartfailureUnited Kingdom
-
Boston Scientific CorporationICON plcCompletedHeartfailureSpain, Belgium, Netherlands, Hong Kong, Italy, France, Finland, Switzerland, Israel, Germany, United Kingdom, Colombia, Singapore, Denmark, Portugal, Japan, Austria, Ireland
-
Mbarara University of Science and TechnologyUniversity of Virginia; Abbott Point of CareCompleted
-
Guy's and St Thomas' NHS Foundation TrustKing's College LondonRecruiting
-
Region StockholmSahlgrenska University Hospital, SwedenRecruitingHemostasis in Decompensated Liver Cirrhosis | Inflammation in Decompensated Liver CirrhosisSweden
-
Central Hospital, Nancy, FranceNot yet recruitingDecompensated Heart FailureFrance
-
Yale UniversityNational Heart, Lung, and Blood Institute (NHLBI)RecruitingDecompensated Heart FailureUnited States
-
Mahidol UniversityRecruitingDecompensated Cirrhosis and AscitesThailand
-
Medical University of WarsawMedical University of Graz; Medical University of Vienna; Poznan University of... and other collaboratorsRecruitingAcute Decompensated Heart FailurePoland
-
Yooyoung Pharmaceutical Co., Ltd.RecruitingAcute Decompensated Heart FailureKorea, Republic of
Clinical Trials on Conventional nasal oxygen
-
Henrik EndemanFranciscus Gasthuis; Maasstad HospitalRecruitingRespiratory Failure | Post Extubation Acute Respiratory Failure Requiring ReintubationNetherlands
-
lu xiaoUnknownHigh-flow Nasal Cannula Oxygen
-
University Magna GraeciaNot yet recruiting
-
University Magna GraeciaNot yet recruiting
-
Hôpital d'enfants Béchir-HamzaUnknownWeaning FailureTunisia
-
Dr. David MasloveIronstone Professional DevelopmentCompleted
-
Second Affiliated Hospital, School of Medicine,...UnknownLung Ultrasound Score | Blunt Thoracic Injury
-
Osaka UniversityOsaka City General Hospital; Osaka Women's and Children's Hospital; Hyogo Prefectural... and other collaboratorsRecruitingPediatric Patients After Cardiothoracic SurgeryJapan
-
The First Affiliated Hospital of Guangzhou Medical...Not yet recruiting
-
Universidade Federal do Rio de JaneiroCompletedCOVID-19 | COVID-19 PneumoniaBrazil